1. Home
  2. CABA vs GAUZ Comparison

CABA vs GAUZ Comparison

Compare CABA & GAUZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CABA
  • GAUZ
  • Stock Information
  • Founded
  • CABA 2017
  • GAUZ 2009
  • Country
  • CABA United States
  • GAUZ Israel
  • Employees
  • CABA N/A
  • GAUZ N/A
  • Industry
  • CABA Biotechnology: Biological Products (No Diagnostic Substances)
  • GAUZ Industrial Machinery/Components
  • Sector
  • CABA Health Care
  • GAUZ Miscellaneous
  • Exchange
  • CABA Nasdaq
  • GAUZ Nasdaq
  • Market Cap
  • CABA 157.4M
  • GAUZ 152.3M
  • IPO Year
  • CABA 2019
  • GAUZ 2024
  • Fundamental
  • Price
  • CABA $1.70
  • GAUZ $6.97
  • Analyst Decision
  • CABA Strong Buy
  • GAUZ Strong Buy
  • Analyst Count
  • CABA 7
  • GAUZ 3
  • Target Price
  • CABA $14.43
  • GAUZ $14.67
  • AVG Volume (30 Days)
  • CABA 1.8M
  • GAUZ 544.2K
  • Earning Date
  • CABA 08-07-2025
  • GAUZ 08-13-2025
  • Dividend Yield
  • CABA N/A
  • GAUZ N/A
  • EPS Growth
  • CABA N/A
  • GAUZ N/A
  • EPS
  • CABA N/A
  • GAUZ N/A
  • Revenue
  • CABA N/A
  • GAUZ $101,165,000.00
  • Revenue This Year
  • CABA N/A
  • GAUZ $28.49
  • Revenue Next Year
  • CABA N/A
  • GAUZ $47.77
  • P/E Ratio
  • CABA N/A
  • GAUZ N/A
  • Revenue Growth
  • CABA N/A
  • GAUZ 18.63
  • 52 Week Low
  • CABA $0.99
  • GAUZ $5.50
  • 52 Week High
  • CABA $7.69
  • GAUZ $13.00
  • Technical
  • Relative Strength Index (RSI)
  • CABA 49.83
  • GAUZ N/A
  • Support Level
  • CABA $1.60
  • GAUZ N/A
  • Resistance Level
  • CABA $1.73
  • GAUZ N/A
  • Average True Range (ATR)
  • CABA 0.11
  • GAUZ 0.00
  • MACD
  • CABA 0.01
  • GAUZ 0.00
  • Stochastic Oscillator
  • CABA 78.57
  • GAUZ 0.00

About CABA Cabaletta Bio Inc.

Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.

About GAUZ Gauzy Ltd. Ordinary Shares

Gauzy Ltd is a fully integrated light and vision control company. Its products include suspended particle device and liquid crystal materials for smart glass applications and AI-powered driver assistance systems, or ADAS, solutions including camera monitoring systems. The company's operating segments are Architecture, Automotive, Safety tech, and Aeronautics. Maximum revenue is generated from its Safety tech segment, which focuses on sales of driver assistance systems for buses, coaches, recreational vehicles, and specific vehicles, such as camera and motion sensor systems, smart mirrors, and safety doors. Geographically, it derives maximum revenue from other European countries (excluding France), followed by the United States, France, Asia, Israel, and other regions.

Share on Social Networks: